跳至主要内容
临床试验/NCT00195429
NCT00195429已完成4 期

A Randomized, Open-label and Multicenter Trial Comparing Withdrawal of Steroids or Tacrolimus From Sirolimus-based Immunosuppressive Regimen in de Novo Renal Allograft Recipients

Wyeth is now a wholly owned subsidiary of Pfizer0 个研究点目标入组 47 人开始时间: 2005年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
47
主要终点
Number of Patients With Biopsy Confirmed Acute Rejection at 12 Months Follow up.

研究概览

简要总结

This study evaluates two different immunosuppression drug regimens in patients with a recent kidney transplant. Patients initially received a regimen of Sirolimus, Tacrolimus and Prednisone and then randomized to discontinue either Tacrolimus or Prednisone.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
13 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • End-stage renal disease, with patients scheduled to receive a kidney transplant.
  • Women who are of childbearing potential who are not pregnant and agree to use a medically acceptable method of contraception throughout the treatment period and for 3 months following discontinuation of study drugs. Any woman becoming pregnant during the treatment period must discontinue the use of study drugs;
  • Signed informed consent.

排除标准

  • Evidence of active systemic or localized major infection at the time of initial study drug administration;
  • Multiple organ transplants;
  • Any pathology or medical condition that can interfere with this protocol study proposal.
  • Other exclusion applies.

研究组 & 干预措施

Sirolimus + Tacrolimus

Experimental

干预措施: Tacrolimus (Drug)

Sirolimus + Tacrolimus

Experimental

干预措施: Sirolimus (Drug)

Sirolimus + Prednisone

Active Comparator

干预措施: Sirolimus (Drug)

Sirolimus + Prednisone

Active Comparator

干预措施: prednisone (Drug)

结局指标

主要结局

Number of Patients With Biopsy Confirmed Acute Rejection at 12 Months Follow up.

时间窗: 12 months

Diagnosis of acute rejection was made via kidney biopsy using the Banff criteria (a standardized model for interpretation of renal allograft biopsies).

次要结局

  • Creatinine Clearance Rate(12 months)

研究者

发起方
Wyeth is now a wholly owned subsidiary of Pfizer
申办方类型
Industry
责任方
Sponsor

相似试验